Similar to risankizumab, these common AEs were observed in plaque psoriasis patients assigned to active treatment arms in clinical trials of other IL-23 inhibitors, IL-17A inhibitors, and TNF inhibitors (16, 30, 33). This evidence concerns the gene IL17A and psoriasis vulgaris.